Morgan Stanley downgraded Adagene (ADAG) to Equal Weight from Overweight with no price target While the firm believes anti-CTLA-4 approaches could drive tumor responses, tolerability remains a key challenge and it is moving to the sidelines and lowering its view of the odds of success for ADG126 based on the relatively small target patient population, regulatory uncertainty, and safety concerns.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAG: